As the androgen receptor (AR) plays an important role in the progression of prostate cancer, mediating the effects of androgens on cellular proliferation and survival,4 a systemic lowering of androgen levels through androgen deprivation therapy (ADT) is the first‐line treatment. This evidence concerns the gene AR and Familial prostate cancer.